To mark this year’s Mental Health Awareness Day we are proud to launch the first video in our new series, One Billion People. In the spirit of prioritizing our mental health, the atai team is taking a company-wide day off. That’s why we are proud to share the video with you today. More than one billion people worldwide suffer from mental health disorders. Many of whom have limited or no effective treatment options, and little hope for a better future. Our new video series shines a light on these individuals, starting with those living with social anxiety disorder, also known as SAD. SAD causes intense fear, self-consciousness and embarrassment in social interactions. The number of people suffering with SAD has dramatically risen over the last few years, affecting 18 million adults in the U.S alone. Despite the growing number of people impacted, there have been no new treatments for more than 20 years. Learn what it’s like to live with SAD, and why those living with it deserve new and effective treatment options. 🎥 #OneBillionPeople #WorldMentalHealthDay To learn more about our programs, visit: https://buff.ly/3U3HEjE
ATAI Life Sciences AG
Biotechnologieforschung
The biotech platform to ultimately cure mental health disorders, enabling people to live healthier and happier lives.
Info
ATAI Life Sciences AG is a global biotech company builder. Based in New York, London and Berlin, our vision is to ultimately cure mental health disorders, enabling people to live healthier and happier lives. Founded in 2018, ATAI takes a decentralized and big data platform approach to drug development - leveraging expertise, access to talent, financial resources and technology, thereby accelerating the pace at which compounds move through early stage clinical trials. ATAI focuses on developing paradigm-shifting and formerly stigmatized compounds with prior evidence for efficacy and safety in humans. The initial focus is on developing solutions for the more than 300 million people who suffer from depression, a significant unmet medical need.
- Website
-
http://www.atai.life
Externer Link zu ATAI Life Sciences AG
- Branche
- Biotechnologieforschung
- Größe
- 51–200 Beschäftigte
- Hauptsitz
- Berlin
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Gegründet
- 2018
- Spezialgebiete
- Biotechnology, psychedelics und mental health disorders
Orte
-
Primär
Wallstrasse 16
ATAI Life Sciences
Berlin, 10179, DE
-
180 Varick St
New York City, New York 10014, US
-
London, GB
Beschäftigte von ATAI Life Sciences AG
-
Robert Ezzell Jr.
Senior Director, Regulatory Affairs
-
Tomy Lorsch
CEO at ComplexChaos, on a mission to help humanity cooperate at scale with collective intelligence.
-
Chris Lee
Global Technology Leader: CISSP|CISM|CRISC|CCNP
-
Claire McNamara
Senior Director, People & Culture
Updates
-
Our Co-Founder, Co-CEO, and Chief Scientific Officer Srinivas Rao will share his insights on the Advancement in Psychedelic Therapies for Neuropsychiatry panel during the 4th Annual Novel Mechanisms in Neuropsychiatry Summit. You can watch the virtual conversation live tomorrow at 10am EST using the link ⬇️ #TDCowenHealthCare #MentalHealth https://lnkd.in/gdfPZXmN
-
Mental health is health. It's as simple as that. Thank you Helen Ouyang, MD, MPH for this important piece which can be perfectly summarized in a sentence: "For people to truly be healthy, modern medicine must prioritize the prevention of mental ailments alongside physical ones." We encourage everyone to read this article. ⬇️ https://lnkd.in/dJFPCQ_y
-
For the first time in seven years, the US has experienced a decline in overdose deaths – seeing a 3% decrease from 2022-2023. This has been a result of the collective efforts of healthcare providers, policymakers, the FDA and communities. On International Overdose Awareness Day, we’re heartened to see such a catastrophic trend has started to reverse. However, we also know that the work is far from over. Over 100,000 lives were still lost in America last year reiterating the need for more effective and accessible support and care options. Our team is hard at work to develop new treatment options that address this unmet need. For more information on overdose trends and prevention, visit https://lnkd.in/gcZ2xcU
International Overdose Awareness Day: 31 August
https://www.overdoseday.com
-
Our Director of Psychotherapeutic Development, Jennifer Tippett, Psy.D. recently spoke with Eamon Armstrong on the Psychedelic Therapy Podcast about psychological support within psychedelic treatment. Drawing from her own experiences working in academic, private practice and now biotechnology, Jennifer contextualizes the need for methodical, rigorous clinical trials to ensure psychedelic medicine is as safe and effective as possible. What we love about this episode is the emphasis she places on finding the safest way for people to access what they need to address their mental health needs. Jennifer and Eamon also talk about: pragmatism, equity and access and sustainability in psychedelic medicine. This episode is a must listen for anyone interested in learning more about why we believe that science and research is the first step to getting this right – getting options to those in need as quickly, but most importantly, as safety as we can. Listen here: https://lnkd.in/eEs85kUE
-
What is a mental health leave of absence? A mental health leave of absence is time a person takes away from work to address a mental health condition such as depression or anxiety. According to ComPsych, the largest global provider of employee mental health services and absence administration, shows there’s been a staggering 300% increase in mental health-related leaves from 2017 to 2023 – with this trend being mainly driven by working women. While it’s clear that there has been a reduction in mental health stigma – and people are able to take time off work to prioritize their mental health there obviously remains a huge barrier to care. We need to be working towards solutions to ideally prevent the need for a mental health leave in the first place. Thanks Jennifer Birdsall, Ph.D., ABPP for sharing these findings and looking for a path forward, for all. https://lnkd.in/g4pTVk33
Simone Biles has really destigmatized mental health leave for millions of women
fortune.com
-
Earlier this week we announced positive topline results from the Phase 1b trial of VLS-01 for patients with treatment-resistance depression. If you’re nerds like us, and are curious about understanding how the compound, N,N-dimethyltryptamine, (DMT) works check out this blog from our co-CEO Srinivas Rao below. ⬇️ https://lnkd.in/gZ_ewtVQ
VLS-01: A proprietary formulation of DMT, a rapid- and short-acting psychedelic, being developed for TRD
Srinivas Rao auf LinkedIn
-
This quarter we made great strides in progressing our clinical-stage assets aimed at addressing significant unmet needs in mental health. This morning we announced positive Phase 1b results for VLS-01 (oral buccal film DMT), with a Phase 2 study in 142 patients with treatment-resistant depression expected to initiate around year end. For a deeper dive into the data, see our August Corporate Presentation linked below. We also announced our clinical development plans for EMP-01 (oral R-MDMA) and expect to initiate a Phase 2 study in social anxiety disorder (SAD) later this year. This follows encouraging Phase 1 results, where EMP-01 demonstrated a unique subjective profile compared to racemic MDMA and classical psychedelics. With no novel molecules approved for SAD in over 20 years, it remains an area of critical unmet need. Full press release: https://lnkd.in/ePtWWAgN August corporate presentation: https://lnkd.in/e27trjSj #MentalHealth #Biotech #EveryoneEverywhere #Q2 #Earnings
-
Today we're pleased to announce positive preliminary results from our Phase 1b trial of VLS-01, our proprietary oral transmucosal film formulation of DMT. We're developing it for patients with treatment-resistant depression (TRD), a condition which impacts the lives of an estimated 100 million people globally. The Phase 1b results support the potential of VLS-01 as a patient-friendly, needle-free, short-duration treatment option that aligns with the two-hour in-clinic paradigm that has been established in interventional psychiatry. The results lay a strong foundation for Phase 2. We've designed a robust trial in 142 patients with TRD, which we expect to initiate around the end of this year. Read the full announcement here: https://lnkd.in/eGfbkBGq #MentalHealth #ClinicalTrials #TreatmentResistantDepression
-
Next week is our annual atai summer shut down. Our team is taking time off – across offices, time zones and departments – to prioritize one of our core values, conscious care. To us, conscious care means maximizing our energy through rest, renewal and rhythm. Again and again science proves that adequate rest (whether this is sleep, dedicated ‘unfocus’ or simply taking a vacation) are vital to both our physical and mental health. Setting aside time for an uninterrupted break is a priority for us so that our team can be as focused, productive and energized as possible.
Ähnliche Seiten
Jobs durchsuchen
Finanzierung
Letzte Runde
Fremdkapital nach Börsengang175.000.000,00 $
Investor:innen
Hercules Capital